Intragastric Balloon-Induced Satiety is Not Mediated by Modification in Fasting or Postprandial Plasma Ghrelin Levels in Morbid Obesity
- First Online:
- Cite this article as:
- Martinez-Brocca, M.A., Belda, O., Parejo, J. et al. OBES SURG (2007) 17: 649. doi:10.1007/s11695-007-9109-z
- 127 Downloads
The BioEnterics Intragastric Balloon (BIB) has been proposed as an adjuvant therapy for the short-term treatment of obesity. The temporal pattern of BIB-induced satiety and whether this effect is mediated by modification of ghrelin levels is unknown.
Patients with treatment-resistant morbid obesity were invited to participate in a randomized, double-blind, sham-controlled trial of 4-month duration. Anthropometric and biochemical parameters, estimation of energy intake, and pre- and postprandial evaluation of satiety were required monthly. Ghrelin response after a standard mixed meal was scheduled prior to and 4 weeks after the endoscopic procedure.
21 out of 22 enrolled patients completed the study (17 women, 5 men; 35.9 ±–.9 years; BMI 50.4 ±–.8 kg/m2). Pre-intervention weight decreased from 143.8 ±–1.2 kg to 131.1 ±–2.6 kg in Group Balloon (P–lt;–.001) and from 138.8 ±–4.5 kg to 129.9 ±–5.6 kg in Group Sham (P–lt;–.01) at the end of the study. Weight loss was not significantly different in Group Balloon and Group Sham at any time-point of the follow-up. Only patients from Group Balloon showed a temporary increased pre- and postprandial satiety, which was maximal at 4 weeks after the intervention. Total area under the curve, fasting and postprandial plasma ghrelin were not significantly different between groups at inclusion or 4 weeks after follow-up. No correlation was found between any of the satiety scores at any time-point with their comparable ghrelin levels.
BIB induces a temporary sense of satiety in morbidly obese patients which is not mediated by modification of fasting or postprandial levels of plasma ghrelin.